Novo and Lilly Win with Positive SELECT CVOT Topline Results

Novo Nordisk announced positive topline results from the SELECT CVOT (view CT.gov record) demonstrating a 20% RRR in 3P-MACE for non-T2DM people with established CVD who were treated with QW 2.4mg semaglutide (Wegovy) compared to placebo. Following the news, Novo’s stock price increased +16%. Novo is anticipated to provide further commentary during its Q2 ’23 earnings call on Thursday, August 10, 2023, at 7:00 AM EST. Below, FENIX provides initial thoughts on the SELECT results, including potential readthrough to Lilly and other manufacturers looking to enter the obesity market.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.